On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®, MacroGenics) in combination with chemotherapy, for the treatment of patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This new approval is based on the SOPHIA trial.
FDA Approves Margetuximab for Metastatic HER2-Positive Breast Cancer
FDA Approves Margenza® Plus Chemotherapy for Pretreated Metastatic HER2-Positive Breast Cancer
Last Modified on September 26, 2023